Comparison of Efficacy and Safety between Long-Acting Injectable Antipsychotic Monotherapy and Combination of Long-Acting Injectable and Oral Antipsychotics in Patients with Schizophrenia.

IF 3.6 Q1 PSYCHIATRY

Schizophrenia Research and Treatment Pub Date : 2021-11-25 eCollection Date: 2021-01-01 DOI:10.1155/2021/8403986

Thanompong Sathienluckana, Pornyupa Tiangpattanawong, Karnpreena Chaiyasukthananoan, Pannapat Jittayanan, Hathaipat Sawetwangsing, Punyawee Puchsaka

{"title":"Comparison of Efficacy and Safety between Long-Acting Injectable Antipsychotic Monotherapy and Combination of Long-Acting Injectable and Oral Antipsychotics in Patients with Schizophrenia.","authors":"Thanompong Sathienluckana, Pornyupa Tiangpattanawong, Karnpreena Chaiyasukthananoan, Pannapat Jittayanan, Hathaipat Sawetwangsing, Punyawee Puchsaka","doi":"10.1155/2021/8403986","DOIUrl":null,"url":null,"abstract":"Background: Long-acting injectable (LAI) antipsychotics are used as a monotherapy in patients with schizophrenia. However, the combination of LAI and oral antipsychotics is commonly used in clinical practice, despite there being very limited studies investigating the efficacy and safety of this combination compared with LAI antipsychotic monotherapy.Objective: To study the efficacy and safety of LAI antipsychotic monotherapy compared with the combination of LAI and oral antipsychotics in patients with schizophrenia.Methods: This study was a retrospective cohort study, which classified eligible patients into two groups: the LAI antipsychotic monotherapy group and the combination of LAI and oral antipsychotic group. The primary outcome was hospitalization between groups. The duration of the study was 2 years.Results: In total, 86 patients completed the study and were analysed (LAI antipsychotic monotherapy group: n = 25; combination of LAI and oral antipsychotic group: n = 61). There was no significant difference in hospitalization between the two groups (P = 1.000). For other outcomes, there were also no significant differences in both all-cause discontinuation (P = 0.667) and adverse drug reactions (P = 0.732) between the two groups.Conclusion: The efficacy and safety of LAI antipsychotic monotherapy appeared similar to the combination of LAI and oral antipsychotics in patients with schizophrenia. Therefore, the combination of LAI and oral antipsychotics, which is commonly used in clinical practice, may not be necessary.","PeriodicalId":45388,"journal":{"name":"Schizophrenia Research and Treatment","volume":null,"pages":null},"PeriodicalIF":3.6000,"publicationDate":"2021-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8639247/pdf/","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Schizophrenia Research and Treatment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2021/8403986","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 3

Abstract

Background: Long-acting injectable (LAI) antipsychotics are used as a monotherapy in patients with schizophrenia. However, the combination of LAI and oral antipsychotics is commonly used in clinical practice, despite there being very limited studies investigating the efficacy and safety of this combination compared with LAI antipsychotic monotherapy.

Objective: To study the efficacy and safety of LAI antipsychotic monotherapy compared with the combination of LAI and oral antipsychotics in patients with schizophrenia.

Methods: This study was a retrospective cohort study, which classified eligible patients into two groups: the LAI antipsychotic monotherapy group and the combination of LAI and oral antipsychotic group. The primary outcome was hospitalization between groups. The duration of the study was 2 years.

Results: In total, 86 patients completed the study and were analysed (LAI antipsychotic monotherapy group: n = 25; combination of LAI and oral antipsychotic group: n = 61). There was no significant difference in hospitalization between the two groups (P = 1.000). For other outcomes, there were also no significant differences in both all-cause discontinuation (P = 0.667) and adverse drug reactions (P = 0.732) between the two groups.

Conclusion: The efficacy and safety of LAI antipsychotic monotherapy appeared similar to the combination of LAI and oral antipsychotics in patients with schizophrenia. Therefore, the combination of LAI and oral antipsychotics, which is commonly used in clinical practice, may not be necessary.

Abstract Image

查看原文本刊更多论文

精神分裂症患者长效注射抗精神病药物单药治疗与长效注射口服抗精神病药物联合治疗的疗效和安全性比较。

背景:长效注射(LAI)抗精神病药物被用作精神分裂症患者的单药治疗。然而，在临床实践中，LAI与口服抗精神病药物的联合使用是常用的，尽管与LAI抗精神病药物单一治疗相比，这种联合使用的有效性和安全性的研究非常有限。目的:比较LAI单药治疗精神分裂症患者与LAI联合口服抗精神病药物治疗的疗效和安全性。方法:本研究采用回顾性队列研究，将符合条件的患者分为LAI抗精神病单药组和LAI联合口服抗精神病药组。主要结局是两组间的住院情况。研究的持续时间为2年。结果:共86例患者完成研究并进行分析(LAI抗精神病单药治疗组:n = 25;LAI联合口服抗精神病药组:n = 61)。两组住院率差异无统计学意义(P = 1.000)。其他结局方面，两组全因停药(P = 0.667)和药物不良反应(P = 0.732)均无显著差异。结论:LAI单药治疗精神分裂症患者的疗效和安全性与LAI联合口服抗精神病药物相似。因此，临床上常用的LAI与口服抗精神病药物联合使用可能没有必要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Schizophrenia Research and Treatment PSYCHIATRY-

CiteScore

4.60

自引率

0.00%

发文量

审稿时长

14 weeks

期刊介绍： Schizophrenia Research and Treatment is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies related to all aspects of schizophrenia.